German prospective registry for patients with chronic myeloid leukemia (CML) previously treated with =2 TKIs switched to another TKI (ASCiminib or ANY ATP-competitive TKI)
Recruiting
- Conditions
- C92.1Chronic myeloid leukaemia [CML], BCR/ABL-positive
- Registration Number
- DRKS00032351
- Lead Sponsor
- Ruprecht-Karls-Universität Heidelberg
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
1. Ph+ or BCR::ABL1 -fusion gene positive CML in chronic phase
2. Prior treatment with = 2 TKIs
3. Decision of the treating physician to switch to a TKI approved for third line CML treatment; the TKI has already been selected by the physician at time of enrollment
4. Switch due to warning or failure (adapted from the 2020 ELN recommendations ) or due to intolerance to the most recent TKI therapy
5. Age = 18 years at the time of change to a new TKI-treatment
6. Signed informed consent prior to participation in this registry
Exclusion Criteria
Existing T315I mutation
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method no endpoints, initially only collection of data in the register. The analysis of the register data is planned for future projects
- Secondary Outcome Measures
Name Time Method